KŌMØ LOCOMOTOR · EVIDENCE-LED GUIDE
Locomotive syndrome is a Japanese framework for recognising reduced mobility related to the locomotor system. Here is what it means, how the three JOA tests classify severity, and what the evidence can — and cannot — tell us. [01][02]
Educational content · JOA framework credited · no online diagnosis · literature reviewed August 2026
01 · THE CONCEPT
The Japanese Orthopaedic Association introduced locomotive syndrome in 2007. It describes reduced ability to stand, walk and move because of disorders or decline within the locomotor system, with increasing risk of future care needs as severity progresses. [01][02]
The concept was created in Japan to make mobility decline visible before loss of independence becomes established. It is a public-health and clinical framework; it does not replace diagnosis of the underlying orthopaedic, neurological or systemic condition.
Movement emerges from an integrated system. A change in one component can be compensated for — until the reserve of the whole system becomes insufficient.
Support, load transmission and fracture resistance.
Range, alignment and efficient transfer of force.
Force, power, endurance and control of movement.
Motor command, sensation, balance and adaptation.
02 · JOA 2020 CRITERIA
The current JOA framework distinguishes no locomotive syndrome (stage 0) and stages 1–3. The overall stage is the most severe result obtained on the Stand-Up Test, Two-Step Test or GLFS-25. [01][04]
All three results remain outside stage 1 thresholds.
Maintain activity and reassess only when useful.A first threshold is reached on at least one component.
Build regular strength, balance and activity habits.Mobility limitation is more established.
A professional assessment is appropriate, especially with pain or falls.Severe limitation is present on at least one component.
Clinical evaluation and treatment of underlying causes are recommended.| Component | Stage 0 | Stage 1 | Stage 2 | Stage 3 |
|---|---|---|---|---|
| Stand-Up Test | Rises from 40 cm on one leg, on both sides | Cannot rise from 40 cm on one leg on one or both sides, but can rise from 20 cm on both legs | Cannot rise from 20 cm on both legs, but can rise from 30 cm | Cannot rise from 30 cm on both legs |
| Two-Step score | ≥ 1.3 | ≥ 1.1 and < 1.3 | ≥ 0.9 and < 1.1 | < 0.9 |
| GLFS-25 | 0–6 | 7–15 | 16–23 | ≥ 24 |
Two-Step score = total length of two maximal steps ÷ height
Two people can reach the same stage for different reasons. Pain, osteoarthritis, spinal or neurological disease, osteoporosis, muscle weakness, balance impairment, deconditioning and other causes require their own clinical assessment.
03 · THE LOCOMOTIVE SYNDROME RISK TEST
One performance test cannot describe the whole person. The JOA combines two physical tests with one patient-reported scale. [01][03]
The person rises from seats 40, 30, 20 and 10 cm high, using both legs and then one leg according to the official sequence. Arms remain folded and the standing position is held for three seconds.
From a marked line, the person takes two consecutive maximal steps, brings the feet together and remains balanced. The distance is measured twice; the better valid attempt is divided by height.
A 25-item self-administered questionnaire explores pain, movement-related difficulty, activities of daily living, social function and psychological concerns over the preceding month.
04 · RELATED, NOT IDENTICAL
These constructs overlap, especially in older adults, but one is not simply the advanced stage of another. [05]
| Framework | Primary focus | Typical assessment | Key distinction |
|---|---|---|---|
| Locomotive syndrome | Mobility decline related to the locomotor system | Stand-Up, Two-Step and GLFS-25 | Broad functional framework originating from the JOA |
| Sarcopenia | Skeletal muscle strength, quantity/quality and physical performance | Grip strength, chair rise, muscle mass and gait/performance criteria | A muscle disorder with international consensus definitions |
| Frailty | Reduced multisystem reserve and vulnerability to stressors | Physical phenotype or multidomain frailty tools | Broader than the locomotor system; definitions vary |
Population studies show substantial coexistence, but also many people with locomotive syndrome who do not meet sarcopenia or frailty criteria.
05 · FROM A RESULT TO A DECISION
The stage is a signal to understand, not a prescription. The useful next step depends on symptoms, causes, goals and safety.
Pain, weakness, joint or spinal disease, neurological signs, medication effects, vision, vestibular function and recent falls can change interpretation.
Progressive lower-limb strengthening, balance work and aerobic activity are commonly used. The JOA’s basic Locomotion Training includes supported single-leg standing and squats.
Rehabilitation, disease-specific treatment, fall-risk reduction, appropriate nutrition and environmental changes may be relevant after assessment.
Longitudinal value comes from standardised technique, the same scoring rules and an interval long enough for meaningful change.
JOA · BASIC LOCOMOTION TRAINING
The JOA presents supported single-leg standing and squats as its basic Locomotion Training. They are general examples, not an individual prescription; pain, recent injury, balance difficulty or medical restrictions call for professional advice. [01]
Stand beside a stable table or chair. Lift one foot slightly without leaning the trunk; keep a fingertip or hand on the support whenever necessary.
Target in the JOA programme: 1 minute on each side, 3 times a day. Safety and control come before duration.With the feet slightly wider than the shoulders, sit the hips back over 2–3 seconds while the knees track over the toes. Keep breathing and return smoothly.
Target in the JOA programme: 5–6 repetitions, 3 times a day. Do not descend beyond comfort; a chair sit-to-stand is an alternative.Individual trials report improvements with exercise and other interventions, but a 2023 systematic review found no strong evidence for one specific intervention across locomotive syndrome. Improvement is possible; “reversal” should never be guaranteed.
06 · WHAT IS ESTABLISHED — AND WHAT IS NOT
The strongest evidence supports the construct and its association with mobility limitation in Japanese populations. Translation into an individual prognosis or a universal screening programme requires caution.
The JOA introduced locomotive syndrome as a framework linking locomotor disorders, mobility and future care needs. [02]
Clinical decision limits were revised to distinguish severe decline affecting social participation. [01]
In the Japanese ROAD cohort, stage 3 was associated with subsequent disability and mortality. This is an association, not an individual forecast. [04]
Most prevalence, threshold and outcome data originate in Japan; estimates should not be transplanted directly to other populations. [08]
Using the updated criteria in the ROAD cohort, mutually exclusive prevalence estimates were 41.3% for stage 1, 14.9% for stage 2 and 11.6% for stage 3. The cohort’s age structure and Japanese context matter. [04]
Cross-sectional studies have identified abnormal test results in working-age adults, but this does not establish benefit from universal screening from age 30. Outside Japan, age thresholds, pathways and cost-effectiveness remain to be established. [06]
JOA definition; three-component framework; 2020 thresholds; associations with mobility limitation.
Prevalence, prognosis and optimal reassessment interval outside Japanese cohorts.
Personalised trajectories, composite scores, movement age and prediction of individual outcomes.
07 · THE KŌMØ LAYER
KŌMØ uses the JOA framework as a credited reference layer. It does not rename locomotive syndrome or alter its thresholds.
Preserve the official Stand-Up, Two-Step and GLFS-25 logic when the Locomo stage is reported.
Relate function to pain, history, goals, environment and the clinician’s examination.
When clinically justified, add supervised gait, neuromuscular, strength, balance or posture measures — clearly labelled as non-JOA data.
Repeat comparable measures over time and make change understandable without claiming deterministic prediction.
The KŌMØ Motion Score, Movement Age and extended measurement architecture are methodological and research outputs under progressive validation. They are not part of the JOA definition and must not be presented as validated diagnostics.
See the KŌMØ clinical pathway08 · ESSENTIAL QUESTIONS
It is a syndrome and functional framework. It can reflect one or several underlying conditions, which still need their own diagnosis.
Mobility and test performance can improve, particularly when modifiable factors and underlying disorders are addressed. The magnitude and durability vary; no page or score can guarantee reversal.
Not automatically. These are not part of the official three-component Locomo classification. A clinician may request them when history and examination suggest a specific indication.
No. Self-observation can start a conversation, but physical tests carry fall risk and the stage does not identify the cause.
There is no universal interval for every person. Repeat testing should be driven by clinical context, intervention and the need to document meaningful change.
No. Locomotive syndrome and its official criteria originate from the Japanese Orthopaedic Association. KŌMØ credits that framework and separates it from its own developing method.
09 · SOURCES
A deliberately short bibliography: the official JOA resource, foundational papers, updated criteria, cohort evidence and intervention review.
Japanese Orthopaedic Association. LOCOMO ONLINE: definition, Locomotive Syndrome Risk Test and Locomotion Training.
Open source ↗Nakamura K. A “super-aged” society and the “locomotive syndrome”. Journal of Orthopaedic Science. 2008;13:1–2.
Open source ↗Seichi A, Hoshino Y, Doi T, et al. Development of the 25-question Geriatric Locomotive Function Scale. Journal of Orthopaedic Science. 2012;17:163–172.
Open source ↗Yoshimura N, Iidaka T, Horii C, et al. Epidemiology of locomotive syndrome using updated clinical decision limits: 6-year follow-ups of the ROAD study. Journal of Bone and Mineral Metabolism. 2022;40:623–635.
Open source ↗Yoshimura N, Muraki S, Iidaka T, et al. Prevalence and co-existence of locomotive syndrome, sarcopenia, and frailty: the ROAD study. Journal of Bone and Mineral Metabolism. 2019;37:1058–1066.
Open source ↗Nishimura A, Ohtsuki M, Kato T, et al. Locomotive syndrome testing in young and middle adulthood. Modern Rheumatology. 2020;30:178–183.
Open source ↗Iwamoto Y, Imura T, Takahashi M, Tanaka R. Interventions to improve locomotive syndrome: a systematic review and meta-analysis of randomized controlled trials. Nagoya Journal of Medical Science. 2023;85:275–288.
Open source ↗Iwamoto Y, Imura T, Hirata K, et al. The risk factors for development or progression of locomotive syndrome: a systematic review. Nagoya Journal of Medical Science. 2025;87:60–75.
Open source ↗Understand the framework.
Keep the person in view.
KŌMØ turns mobility from an isolated result into a clinically responsible, longitudinal conversation.